T-Therapeutics announces Series A extension to $91 million to advance first-in-class bispecifics towards the clinic

13 Nov

Written By Alexandra Collingbourne

Alexandra Collingbourne

ACF Investors: Why raising EIS limits is a budget imperative

Paying it forward: The trailblazing Cambridge entrepreneurs engineering the next wave of global innovators